The acquisition, unanimously approved by both boards of directors, is expected to close by the end of 2026. Viatris intends to fund the purchase primarily through excess cash and short-term borrowings, maintaining its current financial flexibility. For Pacira, the move marks a transition into a larger global infrastructure, with CEO Frank D. Lee noting that Viatris’ scale will accelerate the reach of their opioid-sparing treatments.

Pacira generated approximately $746 million in revenue over the twelve months ending June 30, 2026. By integrating these products, Viatris aims to leverage its expertise in product lifecycle management to bolster its innovative medicines business. The transaction is expected to be immediately accretive to Viatris’ financial metrics, further diversifying its portfolio alongside its existing meloxicam offerings.